Hôpital Guy de Chauliac
- Address
- lock Available on a paid plan
Hôpital Guy de Chauliac - Rare Metabolic Disease Research
Hôpital Guy de Chauliac is a specialized medical research institution with expertise in rare genetic and metabolic disorders. The center focuses on advancing treatment options for patients with complex lysosomal storage diseases through rigorous clinical investigation and innovative therapeutic approaches.
- Hunter Syndrome (Mucopolysaccharidosis Type II) treatment development
- Central nervous system manifestations in metabolic disorders
- Novel enzyme replacement and delivery therapies
The center's research program emphasizes comprehensive evaluation of both CNS and somatic symptoms in rare disease populations. Through systematic assessment of efficacy, safety, and pharmacokinetics, Hôpital Guy de Chauliac contributes to the development of targeted therapies for mucopolysaccharidosis disorders, addressing the critical unmet needs of patients with these devastating conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hôpital Guy de Chauliac
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40 | Moderna Inc. | Phase III | Not Recruiting | Feb 2022 | Nov 2025 |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Idursulfase | 1 | Unknown | 2022-08-24 | 2022-08-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.